<- Go Home
RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Market Cap
$38.2M
Volume
270.6K
Cash and Equivalents
$7.0M
EBITDA
-$12.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$796.0K
Profit Margin
70.88%
52 Week High
$1.45
52 Week Low
$0.70
Dividend
N/A
Price / Book Value
5.73
Price / Earnings
-2.68
Price / Tangible Book Value
5.73
Enterprise Value
$31.4M
Enterprise Value / EBITDA
-2.64
Operating Income
-$12.0M
Return on Equity
225.62%
Return on Assets
-92.60
Cash and Short Term Investments
$7.0M
Debt
$212.0K
Equity
$5.4M
Revenue
$1.1M
Unlevered FCF
-$6.4M
Sector
Biotechnology
Category
N/A